3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
6
Neoplasms
4
Colorectal Neoplasms
4
Stomach Neoplasms
3
Glioma
2
Weight Loss
1
Triple Negative Breast Neoplasms
1
Solid Tumor Cancer
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Refractory Solid Tumors
1
Recurrence
1
Rectal Neoplasms
1
Pseudomyxoma Peritonei
1
Peritoneal Neoplasms
1
Pancreatic cancer, adult
1
Pancreatic Diseases
1
Ovarian Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neuroblastoma
1
Neoplasms, Cystic, Mucinous, and Serous
1
Neoplasm Metastasis
1
Metastatic Pancreatic Adenocarcinoma
1
Mesothelioma
1
Malignant Solid Neoplasm
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Interventions
Gemcitabine
20
Cisplatin
17
pembrolizumab
11
Magnetic Resonance Spectroscopy
7
durvalumab
5
Platinum
5
Irinotecan
5
Fluorouracil
5
1,2-diaminocyclohexaneplatinum II citrate
5
Leucovorin
4
Taxes
3
Oxaliplatin
3
Nivolumab
3
Fluorodeoxyglucose F18
3
Carboplatin
3
Biopsy
3
Bevacizumab
3
spartalizumab
2
pemigatinib
2
ivosidenib
2
fludarabine
2
budigalimab
2
atezolizumab
2
Specimen Handling
2
Radiosurgery
2
Paclitaxel
2
Immunoglobulin G
2
Floxuridine
2
FAPI-46
2
Disulfides
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Cholangiocarcinoma
×
irinotecan sucrosofate
×
Clear all
NCT05277766
2025-07-01
PIPAC-NAL-IRI
University Hospital, Ghent
Phase 1
Recruiting
45 enrolled